Repare Therapeutics announced preliminary Phase 1 LIONS trial data for RP-1664, a PLK4 inhibitor for advanced solid tumors, to be presented at AACR-NCI-EORTC.
Avery Dennison reported a 1.7% rise in Q3 adjusted EPS to $2.37 on $2.2 billion in net sales and provided Q4 adjusted EPS guidance of $2.35 to $2.45.
Phunware appoints Interim CEO Jeremy Krol to its Board of Directors, filling a vacancy and strengthening leadership with his deep business insight.
T1 Energy Inc. reported preliminary Q3 2025 financial results, detailed progress on its G2_Austin facility, and reiterated its full-year EBITDA guidance.
Alkermes plc will acquire Avadel Pharmaceuticals for up to $2.1 billion, consisting of $18.50 cash per share and a contingent value right.
Norwood Financial Corp reported Q3 2025 net income of $8.3 million, an 85% increase, with diluted earnings per share rising to $0.89.